Deciphera Pharmaceuticals (NASDAQ:DCPH) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Tuesday.
DCPH has been the subject of several other research reports. Canaccord Genuity set a $55.00 target price on shares of Deciphera Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 13th. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 21st. Raymond James assumed coverage on shares of Deciphera Pharmaceuticals in a report on Wednesday, August 29th. They issued an “outperform” rating and a $47.00 target price for the company. Cantor Fitzgerald assumed coverage on shares of Deciphera Pharmaceuticals in a report on Wednesday, August 22nd. They issued an “overweight” rating and a $53.00 target price for the company. Finally, B. Riley cut shares of Deciphera Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $43.00 target price for the company. in a report on Tuesday, June 19th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $50.10.
Shares of Deciphera Pharmaceuticals stock opened at $34.74 on Tuesday. Deciphera Pharmaceuticals has a 12-month low of $15.15 and a 12-month high of $45.61. The company has a quick ratio of 18.44, a current ratio of 18.44 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $1.38 billion and a PE ratio of -11.62.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its earnings results on Tuesday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.03. research analysts expect that Deciphera Pharmaceuticals will post -2.59 earnings per share for the current year.
A number of hedge funds have recently added to or reduced their stakes in DCPH. Bank of America Corp DE raised its position in Deciphera Pharmaceuticals by 316.1% in the 2nd quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock valued at $103,000 after purchasing an additional 1,982 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Deciphera Pharmaceuticals in the 1st quarter valued at $152,000. New York State Common Retirement Fund raised its position in Deciphera Pharmaceuticals by 37.5% in the 1st quarter. New York State Common Retirement Fund now owns 9,900 shares of the company’s stock valued at $198,000 after purchasing an additional 2,700 shares during the last quarter. Trexquant Investment LP purchased a new stake in Deciphera Pharmaceuticals in the 2nd quarter valued at $203,000. Finally, Rhumbline Advisers purchased a new stake in Deciphera Pharmaceuticals in the 2nd quarter valued at $301,000. Hedge funds and other institutional investors own 53.49% of the company’s stock.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
See Also: What is a Stop Order?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.